BFM
TARA icon

Boothbay Fund Management’s Protara Therapeutics TARA Stock Holding History

Boothbay Fund Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-88,941
Closed -$470K – 1777
2024
Q4 		$470K Buy
88,941
+71,543
+411% +$231K 0.01% 903
2024
Q3 		$31.8K Sell
17,398
-2,793
-14% -$5.74K ﹤0.01% 1534
2024
Q2 		$42K Sell
20,191
-2,456
-11% -$7.18K ﹤0.01% 1418
2024
Q1 		$90.8K Buy
22,647
+3,783
+20% +$12.2K ﹤0.01% 1430
2023
Q4 		$35.4K Hold
18,864
– – ﹤0.01% 1562
2023
Q3 		$31.5K Hold
18,864
– – ﹤0.01% 1647
2023
Q2 		$45.1K Hold
18,864
– – ﹤0.01% 1678
2023
Q1 		$59K Hold
18,864
– – ﹤0.01% 2009
2022
Q4 		$50.6K Hold
18,864
– – ﹤0.01% 1875
2022
Q3 		$56K Sell
18,864
-6,802
-27% -$23.1K ﹤0.01% 2104
2022
Q2 		$75K Sell
25,666
-1,925
-7% -$7.04K ﹤0.01% 2032
2022
Q1 		$141K Hold
27,591
– – ﹤0.01% 2014
2021
Q4 		$186K Sell
27,591
-19,832
-42% -$137K ﹤0.01% 1512
2021
Q3 		$328K Sell
47,423
-9,460
-17% -$73.7K 0.01% 1286
2021
Q2 		$554K Sell
56,883
-1,343
-2% -$15.2K 0.02% 950
2021
Q1 		$916K Hold
58,226
– – 0.03% 641
2020
Q4 		$1.41M Sell
58,226
-6,457
-10% -$139K 0.05% 373
2020
Q3 		$1.09M Buy
64,683
+20,659
+47% +$479K 0.07% 400
2020
Q2 		$1.29M Buy
44,024
+7,091
+19% +$220K 0.09% 307
2020
Q1 		$849K Buy
+36,933
New +$1.08M 0.07% 339
2019
Q4 		– Sell
-1,440
Closed -$15K – 992
2019
Q3 		$15K Buy
+1,440
New +$20.6K ﹤0.01% 745
2019
Q1 		– Sell
-2,707
Closed -$246K – 878
2018
Q4 		$246K Buy
2,707
+51
+2% +$3.6K 0.04% 437
2018
Q3 		$207K Buy
2,656
+656
+33% +$60.5K 0.02% 651
2018
Q2 		$196K Buy
2,000
+1,249
+166% +$116K 0.02% 636
2018
Q1 		$75K Buy
+751
New +$68.3K 0.01% 654

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Boothbay Fund Management's TARA Position: Q1 2025 in Review

Boothbay Fund Management sold out of Protara Therapeutics (TARA) in Q1 2025, closing a stake of 88,941 shares — an estimated $470K sold.

Boothbay Fund Management first reported a position in TARA in Q1 2018 and held it in 25 quarters. The position peaked at $1.41M in Q4 2020. 59 funds tracked by Wall St. Rank hold TARA as of Q1 2025.

  • Boothbay Fund Management reported no remaining Protara Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 88,941 Protara Therapeutics shares in Q1 2025, an estimated $470K.
  • Boothbay Fund Management first reported a position in Protara Therapeutics in Q1 2018 and held it in 25 quarters.
  • Boothbay Fund Management's Protara Therapeutics position peaked at $1.41M in Q4 2020.
  • 59 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.